IMVT Immunovant, Inc.

QT25

Latest market price

28.41

-0.76-2.61%

Overview Short InterestFilings

IMVTQT25Immunovant, Inc.·NASDAQ

Overview Short InterestFilings

28.41-2.61%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

LGND-4.87%$307.02 BLTE-0.69%$153.67 KOD-1.56%$97.63 MIRM+0.87%$85.74 CGON-4.21%$61.96 ORKA-1.49%$95.43 MANE-7.27%$129.53 RYTM+0.94%$93.44

Snapshot

Index	—	P/E	—	EPS (ttm)	-2.82	Insider Own	—	Shs Outstand	206.55M	Perf Week	0.85%

Market Cap	5.87B	Forward P/E	—	EPS next Y	-2.92	Insider Trans	-0.30%	Shs Float	84.83M	Perf Month	-15.50%

Enterprise Value	5.07B	PEG	—	EPS next Q	-0.74			Short Float	21.54%	Perf Quarter	-27.82%

Income	-539.00M	P/S	—	EPS this Y	—			Short Ratio	13.99	Perf Half Y	2.01%

Sales	7.00M	P/B	7.98	EPS next Y	—	ROA	-63.13%	Short Interest	18.27M	Perf YTD	11.76%

Book/sh	3.56	P/C	7.35	EPS next 5Y	—	ROE	-69.59%	52W High	45.42 -37.45%	Perf Year	14.46%

Cash/sh	3.86	P/FCF	—	EPS past 3/5Y	—	ROIC	-75.90%	52W Low	21.43 32.57%	Perf 3Y	-17.05%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	97.10%	Volatility	3.51% 3.92%	Perf 5Y	246.04%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	-7877.46%	ATR (14)	1.19	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	7.27	Sales Y/Y TTM	—	Profit Margin	-7585.86%	RSI (14)	36.04	Recom	2.26

Dividend Gr. 3/5Y	—	Current Ratio	7.27	EPS Q/Q	-25.00%	SMA20	-2.20%	Beta	0.94	Target Price	40.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	—	SMA50	-17.02%	Rel Volume	0.92	Prev Close	29.17

Employees	315	LT Debt/Eq	0.00	Earnings	Nov 09	SMA200	-11.37%	Avg Volume	1.37M	Price	28.41

IPO Date	Jun 21, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-19.26% 0.00%	Net Debt/EBITDA	—	Volume	1,268,029	Change	-2.61%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-21-26	Reiterated	HC Wainwright & Co.	Buy	$51 → $40
Jan-06-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$50
Dec-18-25	Reiterated	Guggenheim	Buy	$44 → $41
Oct-14-25	Initiated	Truist	Hold	$16
Apr-22-25	Downgrade	UBS	Buy → Neutral
Jan-03-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-10-24	Reiterated	HC Wainwright & Co.	Buy	$51
Jun-03-24	Reiterated	Oppenheimer	Outperform	$46
May-30-24	Reiterated	Guggenheim	Buy	$48
May-30-24	Reiterated	Piper Sandler	Overweight	$57

Latest News· Times ET

Oct-21-26

Oct-21-2607:00AM

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026globenewswire.com

Oct-20-26

Oct-20-2610:14AM

Immunovant (IMVT) Stock Looks Stretched On Book Value AloneYahoo

Oct-14-26

Oct-14-2612:59AM

Immunovant Q1 2027 Earnings Call: Complete TranscriptBenzinga

Oct-12-26

Oct-12-2607:35PM

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firmprnewswire.com

Oct-11-26

Oct-11-2606:00PM

IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Lawgurufocus.com

Oct-08-26

Oct-08-2601:33PM

IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug ClassYahoo

Sep-30-26

Sep-30-2602:06AM

Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's NextYahoo

Sep-25-26

Sep-25-2601:55PM

Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)prnewswire.com

Sep-24-26

Sep-24-2601:51PM

IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Downzacks.com

05:32AM

Roivant reports top-line data from IMVT-1402 CLE trialYahoo

Sep-23-26

Sep-23-2607:00AM

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosusglobenewswire.com

07:00AM

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosusglobenewswire.com

Sep-17-26

Sep-17-2604:18AM

Immunovant Q1 2027 Earnings Call: Complete TranscriptBenzinga

Sep-10-26

Sep-10-2608:52AM

Rosnilimab Emerges as a Potential Advance in Rheumatoid Arthritis as Physicians Look to the Next Wave of Pipeline InnovationYahoo

Aug-27-26

Aug-27-2603:35AM

Algert Global LLC Raises Position in Immunovant, Inc. $IMVTdefenseworld.net

Company

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2026 3/31/2026	FY 2025 3/31/2025	FY 2024 3/31/2024	FY 2023 3/31/2023	FY 2022 3/31/2022	FY 2021 3/31/2021	FY 2020 3/31/2020	FY 2019 3/31/2019
Total Revenue	7	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	0	—	—	—	—	—
Gross Profit	7	0	0	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	68	76	77	57	—	—	—	—	—
Research and Development	498	457	361	213	—	—	—	—	—
Other Operating Expense	0	0	0	0	—	—	—	—	—
Operating Income	-559	-533	-438	-270	—	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	20	28	25	11	—	—	—	—	—
Net Income Before Taxes	-539	-505	-413	-259	—	—	—	—	—
Income Taxes	0	0	1	1	—	—	—	—	—
Consolidated Net Income	-539	-506	-414	-259	—	—	—	—	—
Net Income From Continuing Operations	-539	-506	-414	-259	—	—	—	—	—
Net Income	-539	-506	-414	-259	—	—	—	—	—
EPS (Recurring)	-2.82	-2.77	-2.73	-1.88	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-2.82	-2.77	-2.73	-1.88	—	—	—	—	—
EPS (Diluted)	-2.82	-2.77	-2.73	-1.88	—	—	—	—	—
EBITDA	-539	-505	-413	-259	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	836.07	—	—	—	—	—	—	—	—
Gross Margin	100.00	—	—	—	—	—	—	—	—
Operating Margin	-7,985.71	—	—	—	—	—	—	—	—
Net Margin	-7,700.00	—	—	—	—	—	—	—	—
Shares Outstanding	206	182	152	138	—	—	—	—	—
Market Capitalization	5,852	4,521	2,598	4,459	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Girao Tiago	Chief Financial Officer	Oct 28 '26	Sale	28.50	6,606	188,271	234,192	Oct 30
Stout Jay S	Chief Technology Officer	Oct 21 '26	Sale	28.94	2,595	75,099	198,937	Oct 23
Van Tuyl Christopher	Chief Legal Officer	Oct 07 '26	Sale	32.06	1,327	42,544	175,218	Oct 09
Gloria Melanie	Chief Operating Officer	Oct 07 '26	Sale	32.06	2,241	71,846	217,060	Oct 09
Stout Jay S	Chief Technology Officer	Oct 07 '26	Sale	32.06	3,809	122,117	201,532	Oct 09
Venker Eric	Chief Executive Officer	Oct 02 '26	Sale	34.11	3,506	119,590	257,075	Oct 05
Venker Eric	Chief Executive Officer	Oct 01 '26	Option Exercise	14.46	92,187	1,333,024	346,467	Oct 05
Van Tuyl Christopher	Chief Legal Officer	Sep 23 '26	Sale	36.36	2,846	103,481	176,545	Sep 25
Pande Atul	Director	Aug 28 '26	Option Exercise	8.43	1,500	12,645	118,231	Aug 28
Pande Atul	Director	Aug 28 '26	Sale	43.27	1,500	64,905	116,731	Aug 28
Gloria Melanie	Chief Operating Officer	Aug 20 '26	Sale	44.16	3,056	134,953	219,301	Aug 21
Pande Atul	Director	Jul 24 '26	Sale	39.80	1,500	59,700	116,731	Jul 24
Pande Atul	Director	Jul 24 '26	Option Exercise	8.43	1,500	12,645	118,231	Jul 24
Girao Tiago	Chief Financial Officer	Jul 23 '26	Sale	38.69	6,798	263,015	240,798	Jul 24
Stout Jay S	Chief Technology Officer	Jul 23 '26	Sale	38.69	2,857	110,537	205,341	Jul 24

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.